Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Update

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totalling 1,040,000 shares, a decline of 39.2% from the March 31st total of 1,710,000 shares. Approximately 1.1% of the company's stock are short sold. Based on an average daily trading volume, of 957,300 shares, the days-to-cover ratio is currently 1.1 days.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp lifted its stake in shares of Unicycive Therapeutics by 142.4% during the 4th quarter. Northern Trust Corp now owns 58,181 shares of the company's stock worth $46,000 after buying an additional 34,183 shares during the last quarter. Virtu Financial LLC lifted its position in Unicycive Therapeutics by 566.8% during the third quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock worth $30,000 after acquiring an additional 62,881 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Unicycive Therapeutics by 142.2% during the fourth quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock worth $136,000 after acquiring an additional 100,679 shares during the period. Geode Capital Management LLC grew its position in shares of Unicycive Therapeutics by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after purchasing an additional 122,089 shares during the last quarter. Finally, Acuta Capital Partners LLC increased its stake in shares of Unicycive Therapeutics by 16.4% during the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock worth $1,829,000 after purchasing an additional 323,801 shares during the period. 40.42% of the stock is owned by institutional investors.

Unicycive Therapeutics Stock Up 0.3 %

Shares of UNCY stock traded up $0.00 on Friday, reaching $0.65. The stock had a trading volume of 485,088 shares, compared to its average volume of 1,456,225. Unicycive Therapeutics has a 12 month low of $0.20 and a 12 month high of $1.21. The firm has a market capitalization of $78.06 million, a price-to-earnings ratio of -0.67 and a beta of 2.15. The firm's 50-day moving average is $0.59 and its two-hundred day moving average is $0.60.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13). On average, sell-side analysts forecast that Unicycive Therapeutics will post -0.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on UNCY shares. HC Wainwright restated a "buy" rating and issued a $7.50 price objective on shares of Unicycive Therapeutics in a report on Friday, April 11th. Guggenheim started coverage on Unicycive Therapeutics in a research note on Monday, April 21st. They set a "buy" rating and a $6.00 price objective on the stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.